Do analysts prefer OBSV or LSTA?

Lisata Therapeutics has a consensus price target of $15.00, suggesting a potential upside of 333.03%. Given Lisata Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Lisata Therapeutics is more favorable than ObsEva. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ObsEva 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Lisata Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Is OBSV or LSTA more profitable?

Lisata Therapeutics' return on equity of -103.54% beat ObsEva's return on equity. Company Net Margins Return on Equity Return on Assets ObsEva N/A -416.36% -92.01% Lisata Therapeutics N/A -103.54% -83.08%

Do analysts prefer APLM or OBSV?

Given ObsEva's higher possible upside, analysts plainly believe ObsEva is more favorable than Apollomics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ObsEva 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings & valuation, APLM or OBSV?

Apollomics has higher revenue and earnings than ObsEva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Apollomics $8.50M 3.55 -$10.94M N/A N/A ObsEva N/A N/A -$58.38M -$0.92 N/A

Is APLM or OBSV more profitable?

Apollomics' return on equity of 0.00% beat ObsEva's return on equity. Company Net Margins Return on Equity Return on Assets Apollomics N/A N/A N/A ObsEva N/A -416.36% -92.01%

Is CPHI or OBSV more profitable?

ObsEva has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. China Pharma's return on equity of -63.93% beat ObsEva's return on equity. Company Net Margins Return on Equity Return on Assets China Pharma -85.56% -63.93% -31.42% ObsEva N/A -416.36% -92.01%

Do analysts recommend EVAX or OBSV?

Evaxion A/S currently has a consensus target price of $11.00, indicating a potential upside of 200.55%. Given Evaxion A/S's stronger consensus rating and higher probable upside, analysts plainly believe Evaxion A/S is more favorable than ObsEva. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evaxion A/S 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 ObsEva 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings & valuation, EVAX or OBSV?

Evaxion A/S has higher revenue and earnings than ObsEva. Evaxion A/S is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Evaxion A/S $7.53M 4.05 -$7.71M -$1.47 N/A ObsEva N/A N/A -$58.38M -$0.92 N/A

Is EVAX or OBSV more profitable?

Evaxion A/S's return on equity of -73.56% beat ObsEva's return on equity. Company Net Margins Return on Equity Return on Assets Evaxion A/S N/A -73.56% -37.45% ObsEva N/A -416.36% -92.01%

Do analysts rate QUCY or OBSV?

Given ObsEva's higher possible upside, analysts clearly believe ObsEva is more favorable than Mainz Biomed. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 ObsEva 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation and earnings, QUCY or OBSV?

Mainz Biomed has higher revenue and earnings than ObsEva. Mainz Biomed is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mainz Biomed $537.08K 57.46 -$16.21M -$47.60 N/A ObsEva N/A N/A -$58.38M -$0.92 N/A

Is QUCY or OBSV more profitable?

Mainz Biomed's return on equity of 0.00% beat ObsEva's return on equity. Company Net Margins Return on Equity Return on Assets Mainz Biomed N/A N/A N/A ObsEva N/A -416.36% -92.01%

ObsEva (OBSV) Competitors

Compare

OBSV vs. LSTA, APLM, CPHI, EVAX, and QUCY

Should you buy ObsEva stock or one of its competitors? MarketBeat compares ObsEva with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ObsEva include Lisata Therapeutics (LSTA), Apollomics (APLM), China Pharma (CPHI), Evaxion A/S (EVAX), and Mainz Biomed (QUCY). These companies are all part of the "pharmaceutical products" industry.

How does ObsEva compare to Lisata Therapeutics?

ObsEva (NASDAQ:OBSV) and Lisata Therapeutics (NASDAQ:LSTA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, media sentiment, valuation, institutional ownership, earnings and dividends.

Lisata Therapeutics has higher revenue and earnings than ObsEva. Lisata Therapeutics is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ObsEva	N/A	N/A	-$58.38M	-$0.92	N/A
Lisata Therapeutics	$170K	185.55	-$16.59M	-$1.86	N/A

ObsEva has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market. Comparatively, Lisata Therapeutics has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market.

17.5% of ObsEva shares are owned by institutional investors. Comparatively, 8.9% of Lisata Therapeutics shares are owned by institutional investors. 14.4% of ObsEva shares are owned by insiders. Comparatively, 9.6% of Lisata Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Lisata Therapeutics had 6 more articles in the media than ObsEva. MarketBeat recorded 6 mentions for Lisata Therapeutics and 0 mentions for ObsEva. Lisata Therapeutics' average media sentiment score of 0.81 beat ObsEva's score of 0.00 indicating that Lisata Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
ObsEva	Neutral
Lisata Therapeutics	Positive

Lisata Therapeutics' return on equity of -103.54% beat ObsEva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ObsEva	N/A	-416.36%	-92.01%
Lisata Therapeutics	N/A	-103.54%	-83.08%

Lisata Therapeutics has a consensus price target of $15.00, suggesting a potential upside of 333.03%. Given Lisata Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Lisata Therapeutics is more favorable than ObsEva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ObsEva	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Lisata Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Summary

Lisata Therapeutics beats ObsEva on 9 of the 13 factors compared between the two stocks.

How does ObsEva compare to Apollomics?

Apollomics (NASDAQ:APLM) and ObsEva (NASDAQ:OBSV) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, media sentiment, risk, institutional ownership and earnings.

Apollomics' return on equity of 0.00% beat ObsEva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apollomics	N/A	N/A	N/A
ObsEva	N/A	-416.36%	-92.01%

19.1% of Apollomics shares are held by institutional investors. Comparatively, 17.5% of ObsEva shares are held by institutional investors. 14.4% of ObsEva shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Given ObsEva's higher possible upside, analysts plainly believe ObsEva is more favorable than Apollomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ObsEva	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Apollomics had 2 more articles in the media than ObsEva. MarketBeat recorded 2 mentions for Apollomics and 0 mentions for ObsEva. Apollomics' average media sentiment score of 1.44 beat ObsEva's score of 0.00 indicating that Apollomics is being referred to more favorably in the media.

Company	Overall Sentiment
Apollomics	Positive
ObsEva	Neutral

Apollomics has a beta of 1.53, suggesting that its stock price is 53% more volatile than the broader market. Comparatively, ObsEva has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market.

Apollomics has higher revenue and earnings than ObsEva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apollomics	$8.50M	3.55	-$10.94M	N/A	N/A
ObsEva	N/A	N/A	-$58.38M	-$0.92	N/A

Summary

Apollomics beats ObsEva on 9 of the 11 factors compared between the two stocks.

How does ObsEva compare to China Pharma?

China Pharma (NYSE:CPHI) and ObsEva (NASDAQ:OBSV) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability.

China Pharma has higher revenue and earnings than ObsEva. China Pharma is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China Pharma	$3.99M	7.91	-$3.08M	-$0.55	N/A
ObsEva	N/A	N/A	-$58.38M	-$0.92	N/A

17.5% of ObsEva shares are held by institutional investors. 6.4% of China Pharma shares are held by company insiders. Comparatively, 14.4% of ObsEva shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

China Pharma has a beta of 1.16, indicating that its stock price is 16% more volatile than the broader market. Comparatively, ObsEva has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market.

ObsEva has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. China Pharma's return on equity of -63.93% beat ObsEva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
China Pharma	-85.56%	-63.93%	-31.42%
ObsEva	N/A	-416.36%	-92.01%

In the previous week, China Pharma's average media sentiment score of 0.32 beat ObsEva's score of 0.00 indicating that China Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
China Pharma	Neutral
ObsEva	Neutral

Summary

China Pharma beats ObsEva on 7 of the 11 factors compared between the two stocks.

How does ObsEva compare to Evaxion A/S?

Evaxion A/S (NASDAQ:EVAX) and ObsEva (NASDAQ:OBSV) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

Evaxion A/S has higher revenue and earnings than ObsEva. Evaxion A/S is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evaxion A/S	$7.53M	4.05	-$7.71M	-$1.47	N/A
ObsEva	N/A	N/A	-$58.38M	-$0.92	N/A

Evaxion A/S currently has a consensus target price of $11.00, indicating a potential upside of 200.55%. Given Evaxion A/S's stronger consensus rating and higher probable upside, analysts plainly believe Evaxion A/S is more favorable than ObsEva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evaxion A/S	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
ObsEva	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Evaxion A/S has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market. Comparatively, ObsEva has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market.

11.0% of Evaxion A/S shares are owned by institutional investors. Comparatively, 17.5% of ObsEva shares are owned by institutional investors. 41.6% of Evaxion A/S shares are owned by company insiders. Comparatively, 14.4% of ObsEva shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Evaxion A/S's return on equity of -73.56% beat ObsEva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evaxion A/S	N/A	-73.56%	-37.45%
ObsEva	N/A	-416.36%	-92.01%

In the previous week, Evaxion A/S had 3 more articles in the media than ObsEva. MarketBeat recorded 3 mentions for Evaxion A/S and 0 mentions for ObsEva. Evaxion A/S's average media sentiment score of 0.63 beat ObsEva's score of 0.00 indicating that Evaxion A/S is being referred to more favorably in the media.

Company	Overall Sentiment
Evaxion A/S	Positive
ObsEva	Neutral

Summary

Evaxion A/S beats ObsEva on 10 of the 14 factors compared between the two stocks.

How does ObsEva compare to Mainz Biomed?

Mainz Biomed (NASDAQ:QUCY) and ObsEva (NASDAQ:OBSV) are both small-cap pharmaceutical preparations industry companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

In the previous week, Mainz Biomed had 6 more articles in the media than ObsEva. MarketBeat recorded 6 mentions for Mainz Biomed and 0 mentions for ObsEva. Mainz Biomed's average media sentiment score of 0.57 beat ObsEva's score of 0.00 indicating that Mainz Biomed is being referred to more favorably in the media.

Company	Overall Sentiment
Mainz Biomed	Positive
ObsEva	Neutral

Mainz Biomed has a beta of 2.22, suggesting that its share price is 122% more volatile than the broader market. Comparatively, ObsEva has a beta of 0.68, suggesting that its share price is 32% less volatile than the broader market.

Mainz Biomed's return on equity of 0.00% beat ObsEva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mainz Biomed	N/A	N/A	N/A
ObsEva	N/A	-416.36%	-92.01%

Given ObsEva's higher possible upside, analysts clearly believe ObsEva is more favorable than Mainz Biomed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
ObsEva	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Mainz Biomed has higher revenue and earnings than ObsEva. Mainz Biomed is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mainz Biomed	$537.08K	57.46	-$16.21M	-$47.60	N/A
ObsEva	N/A	N/A	-$58.38M	-$0.92	N/A

17.5% of ObsEva shares are held by institutional investors. 3.1% of Mainz Biomed shares are held by insiders. Comparatively, 14.4% of ObsEva shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Mainz Biomed beats ObsEva on 8 of the 13 factors compared between the two stocks.

Get ObsEva News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OBSV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OBSV vs. The Competition

Export

Metric	ObsEva	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$7.94M	$968.72M	$6.48B	$12.36B
Dividend Yield	N/A	4.84%	2.67%	5.66%
P/E Ratio	0.00	1.46	23.95	24.60
Price / Sales	N/A	123.53	536.37	171.61
Price / Cash	N/A	20.06	27.48	37.92
Price / Book	N/A	8.01	10.44	6.77
Net Income	-$58.38M	-$4.88M	$3.56B	$337.32M

ObsEva Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OBSV ObsEva	N/A	N/A	N/A	N/A	$7.94M	N/A	N/A	50
LSTA Lisata Therapeutics	2.2901 of 5 stars	$3.61 +4.3%	$15.00 +315.5%	+42.3%	$31.51M	$170K	N/A	30	High Trading Volume
APLM Apollomics	1.6644 of 5 stars	$13.82 -3.3%	N/A	+114.7%	$31.40M	$8.50M	N/A	45	Positive News Short Interest Decrease Gap Down
CPHI China Pharma	N/A	$0.77 +7.1%	N/A	-56.2%	$31.04M	$3.99M	N/A	250
EVAX Evaxion A/S	3.4906 of 5 stars	$3.79 +4.4%	$11.00 +190.2%	+31.4%	$30.27M	$7.53M	N/A	60

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OBSV) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ObsEva (OBSV) Competitors

OBSV vs. LSTA, APLM, CPHI, EVAX, and QUCY

How does ObsEva compare to Lisata Therapeutics?

Summary

How does ObsEva compare to Apollomics?

Summary

How does ObsEva compare to China Pharma?

Summary

How does ObsEva compare to Evaxion A/S?

Summary

How does ObsEva compare to Mainz Biomed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OBSV vs. The Competition

ObsEva Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ObsEva (OBSV) Competitors

OBSV vs. LSTA, APLM, CPHI, EVAX, and QUCY

How does ObsEva compare to Lisata Therapeutics?

Which has better earnings and valuation, OBSV or LSTA?

Which has more volatility and risk, OBSV or LSTA?

Do institutionals and insiders hold more shares of OBSV or LSTA?

Does the media prefer OBSV or LSTA?

Is OBSV or LSTA more profitable?

Do analysts prefer OBSV or LSTA?

Summary

How does ObsEva compare to Apollomics?

Is APLM or OBSV more profitable?

Do insiders & institutionals hold more shares of APLM or OBSV?

Do analysts prefer APLM or OBSV?

Does the media favor APLM or OBSV?

Which has more risk and volatility, APLM or OBSV?

Which has stronger earnings & valuation, APLM or OBSV?

Summary

How does ObsEva compare to China Pharma?

Which has preferable earnings and valuation, CPHI or OBSV?

Do institutionals & insiders hold more shares of CPHI or OBSV?

Which has more volatility & risk, CPHI or OBSV?

Is CPHI or OBSV more profitable?

Does the media favor CPHI or OBSV?

Summary

How does ObsEva compare to Evaxion A/S?

Which has preferable earnings & valuation, EVAX or OBSV?

Do analysts recommend EVAX or OBSV?

Which has more volatility & risk, EVAX or OBSV?

Do insiders and institutionals believe in EVAX or OBSV?

Is EVAX or OBSV more profitable?

Does the media favor EVAX or OBSV?

Summary

How does ObsEva compare to Mainz Biomed?

Does the media prefer QUCY or OBSV?

Which has more risk and volatility, QUCY or OBSV?

Is QUCY or OBSV more profitable?

Do analysts rate QUCY or OBSV?

Which has better valuation and earnings, QUCY or OBSV?

Do insiders & institutionals believe in QUCY or OBSV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OBSV vs. The Competition

ObsEva Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools